Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGTX Cognition Therapeutics	$0.57 -6.1%	$0.35	$0.22 ▼ $2.54	$37.51M	0.88	4.09 million shs	4.05 million shs
COYA Coya Therapeutics	$6.05 -1.8%	$5.81	$4.65 ▼ $10.24	$103.03M	0.26	72,963 shs	66,361 shs
CTNM Contineum Therapeutics	$3.77 +1.1%	$4.04	$3.35 ▼ $21.92	$96.50M	0.85	91,086 shs	118,856 shs
TNYA Tenaya Therapeutics	$0.69 -3.0%	$0.55	$0.36 ▼ $4.06	$115.72M	3	2.74 million shs	2.42 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGTX Cognition Therapeutics	-6.12%	-3.48%	+90.41%	+52.20%	-70.42%
COYA Coya Therapeutics	-1.79%	+0.83%	+7.46%	+15.90%	-21.43%
CTNM Contineum Therapeutics	+1.07%	-3.83%	-14.90%	-13.93%	-82.05%
TNYA Tenaya Therapeutics	-3.01%	+9.04%	+16.65%	+49.38%	-80.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGTX Cognition Therapeutics	2.9299 of 5 stars	3.5	3.0	3.2	1.7	0.6
COYA Coya Therapeutics	1.9444 of 5 stars	3.5	3.0	2.0	0.8	0.0
CTNM Contineum Therapeutics	3.65 of 5 stars	3.6	5.0	3.6	0.8	1.3
TNYA Tenaya Therapeutics	3.4 of 5 stars	3.5	3.0	1.4	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGTX Cognition Therapeutics	3.00	Buy	$2.83	398.83% Upside
COYA Coya Therapeutics	3.00	Buy	$16.50	172.73% Upside
CTNM Contineum Therapeutics	3.17	Buy	$22.50	496.82% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	805.80% Upside

Current Analyst Ratings Breakdown

Latest CGTX, CTNM, COYA, and TNYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	COYA Coya Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/26/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00
5/15/2025	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/9/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.31 per share	N/A
COYA Coya Therapeutics	$3.55M	28.51	N/A	N/A	$2.37 per share	2.55
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	$7.66 per share	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$1.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGTX Cognition Therapeutics	-$33.97M	-$0.74	N/A	N/A	N/A	N/A	-194.42%	-115.14%	8/6/2025 (Estimated)
COYA Coya Therapeutics	-$14.88M	-$1.07	N/A	N/A	N/A	N/A	-48.88%	-43.32%	8/11/2025 (Estimated)
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
TNYA Tenaya Therapeutics	-$111.13M	-$1.16	N/A	N/A	N/A	N/A	-92.20%	-74.53%	8/14/2025 (Estimated)

Latest CGTX, CTNM, COYA, and TNYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	N/A	N/A	N/A	$7.50 million	N/A
8/11/2025	Q2 2025	COYA Coya Therapeutics	-$0.22	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/7/2025	Q1 2025	TNYA Tenaya Therapeutics	-$0.18	-$0.24	-$0.06	-$0.24	N/A	N/A
5/6/2025	Q1 2025	CGTX Cognition Therapeutics	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGTX Cognition Therapeutics	N/A	2.09	2.09
COYA Coya Therapeutics	N/A	8.84	8.84
CTNM Contineum Therapeutics	N/A	21.47	21.47
TNYA Tenaya Therapeutics	N/A	6.68	6.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGTX Cognition Therapeutics	43.35%
COYA Coya Therapeutics	39.75%
CTNM Contineum Therapeutics	N/A
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
CGTX Cognition Therapeutics	14.40%
COYA Coya Therapeutics	12.00%
CTNM Contineum Therapeutics	11.30%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGTX Cognition Therapeutics	20	61.99 million	53.07 million	Not Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
TNYA Tenaya Therapeutics	110	162.67 million	83.53 million	Optionable

CGTX, CTNM, COYA, and TNYA Headlines

Recent News About These Companies

Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $6.25

July 10, 2025 | americanbankingnews.com

TNYA - Tenaya Therapeutics Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

TNYA - Tenaya Therapeutics Inc Trailing Returns - Morningstar

July 8, 2025 | morningstar.comM

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Rating of "Buy" from Analysts

July 7, 2025 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 0.3% - Here's Why

July 4, 2025 | marketbeat.com

Tenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Tenaya Therapeutics, Inc. (TNYA) Cash Flow - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025 | finanznachrichten.de

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 15, 2025 | globenewswire.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%

May 15, 2025 | aaii.comA

Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting

May 15, 2025 | nasdaq.com

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

May 13, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)

May 11, 2025 | theglobeandmail.com

We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

May 10, 2025 | finance.yahoo.com

Tenaya Therapeutics Reports Q1 2025 Financial Results

May 8, 2025 | tipranks.com

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | finance.yahoo.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.03%

May 2, 2025 | aaii.comA

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.21%

April 30, 2025 | aaii.comA

H.C. Wainwright maintains Buy on Tenaya Therapeutics stock

April 26, 2025 | investing.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%

April 26, 2025 | aaii.comA

Tenaya announces interim data from ongoing RIDGE study

April 25, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, CTNM, COYA, and TNYA Company Descriptions

Cognition Therapeutics NASDAQ:CGTX

$0.57 -0.04 (-6.12%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$0.58 +0.01 (+1.41%)

As of 04:02 AM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Coya Therapeutics NASDAQ:COYA

$6.05 -0.11 (-1.79%)

Closing price 07/15/2025 03:59 PM Eastern

Extended Trading

$6.21 +0.16 (+2.71%)

As of 07/15/2025 07:56 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Contineum Therapeutics NASDAQ:CTNM

$3.77 +0.04 (+1.07%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$3.94 +0.18 (+4.64%)

As of 07/15/2025 06:23 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Tenaya Therapeutics NASDAQ:TNYA

$0.69 -0.02 (-3.01%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$0.70 +0.01 (+1.88%)

As of 04:02 AM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time